REVBW — REVELATION BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1810560 ·
Last close
$0.01
Market Cap
—
52W High
—
52W Low
—
ADV30
66,524
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,662,241 | -3,323,384 | 12,497,932 | 11,482,792 | 2,430,946 |
| Mar 2026 | 0 | — | -3,092,500 | -3,009,051 | 15,044,282 | 14,113,415 | 2,055,329 |
| Dec 2025 | 0 | — | -2,571,588 | -2,511,006 | 11,582,924 | 10,700,331 | 2,721,929 |
| Sep 2025 | 0 | — | -1,943,011 | -1,907,176 | 12,856,342 | 12,708,489 | 1,854,507 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,690,025
Investing CF
$-71,879
Financing CF
$19,170,708
CapEx
$-71,879
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-52,428,338
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-10,068,328
Pretax Income TTM
$-9,871,615
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,070,814 | -8,913,649 | 11,582,924 | 2,721,929 | 8,860,995 | -8,269,581 |
| Dec 2024 | 0 | -7,975,109 | -15,038,536 | 6,622,049 | 1,913,667 | 4,708,382 | -18,321,276 |
| Dec 2023 | 0 | -8,656,664 | -120,254 | 12,212,609 | 5,564,894 | 6,647,715 | -7,286,286 |
| Dec 2022 | 0 | -10,864,511 | -10,829,549 | 5,503,415 | 4,450,962 | 1,052,453 | -11,219,396 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1183.46 | — |
| JNJ | JOHNSON & JOHNSON | $653.61B | $271.22 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
News headlines (Yahoo Finance, 1h cache)
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
2026-08-19 13:00 · Yahoo
REVB Approaching a Critical Inflection Point
2026-08-07 12:14 · Yahoo
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
2026-08-06 20:15 · Yahoo
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
2026-08-03 13:00 · Yahoo
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-21 20:05 · Yahoo
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
2026-07-10 20:05 · Yahoo
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
2026-06-01 13:00 · Yahoo
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
2026-05-11 13:00 · Yahoo
REVB Poised for Big Year
2026-05-08 12:04 · Yahoo
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
2026-05-07 20:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.